Unlock instant, AI-driven research and patent intelligence for your innovation.
Dihydropyrazolone compound as well as preparation method and medical application thereof
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A compound and mixture technology, applied in the field of medicine, can solve the problem of low activity
Active Publication Date: 2019-04-30
NAT INST OF PHARMA R & D CO LTD
View PDF3 Cites 4 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
However, these compounds generally have disadvantages such as low activity
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0173] Example 1: 2-(6-(2-thia-6-aza-spiro[3.3]hept-6-yl)pyrimidin-4-yl)-4-(1H-1,2,3-triazole Preparation of -1-yl)-1,2-dihydro-3H-pyrazol-3-one
[0174]
[0175] Step 1: Synthesis of ethyl 2-(1H-1,2,3-triazol-1-yl)acetate (Intermediate 1A)
[0176] Add 1H-1,2,3-triazole (100 g, 1.45 mol) into a 1 L reaction flask, add ethyl acetate (300 mL), DIPEA (252 mL, 1.45 mol) therein, and stir for 3 minutes under ice cooling. Ethyl bromoacetate (152 mL, 1.38 mol) was added into 200 mL of ethyl acetate, and then it was slowly added dropwise into the reaction flask. After the dropwise addition was completed, it was stirred overnight at room temperature. After the reaction was complete, filter, wash the filtrate once with water and saturated brine, dry over anhydroussodiumsulfate, filter, and concentrate the filtrate under reduced pressure to obtain 100 g of the title product as a yellow oil, yield: 44.3%.
[0177] Step 2: Synthesis of ethyl 3-(dimethylamino)-2-(1H-1,2,3-triazol-1-...
Embodiment 2
[0187] Example 2: 2-(6-(2,2-dioxo-2-thia-6-aza-spiro[3.3]hept-6-yl)pyrimidin-4-yl)-4-(1H-1 , Preparation of 2,3-triazol-1-yl)-1,2-dihydro-3H-pyrazol-3-one
[0188]
[0189] The same preparation method as in Example 1, except that 2-thia-6-aza-spiro[3.3]heptane-2,2-dioxide hydrochloride was used instead of 2-thia-6-azaspiro[ 3.3] Heptane hemioxalate to give the title compound.
[0190] MS:m / z=375.4[M+H] + .
[0191] 1 H NMR(300MHz,DMSO):δppm 4.35(m,4H),4.50(m,4H),7.18(s,1H),7.80(s,1H),8.08(s,1H),8.38(s,1H) ,8.46(s,1H).
Embodiment 3
[0192] Example 3: 2-(6-(2,6-diazaspiro[3.3]heptane-2-yl)pyrimidin-4-yl)-4-(1H-1,2,3-triazole-1 Preparation of -yl)-1,2-dihydro-3H-pyrazol-3-one
[0193]
[0194] The preparation method is the same as in Example 1, except that 2,6-diazaspiro[3.3]heptane-2-carboxylate tert-butyl hemioxalate is used instead of 2-thia-6-azaspiro[3.3] Heptane hemioxalate to give the title compound.
[0195] MS:m / z=326.2[M+H] + .
[0196] 1 H NMR(300MHz,DMSO):δppm 4.20(m,4H),4.36(m,4H),7.00(s,1H),7.86(s,1H),8.26(s,1H),8.36(s,1H) ,8.49(s,1H).
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention relates to a dihydropyrazolone compound as well as a preparation method and medical application thereof, in particularly relates to a general formula (I) compound shown in the specification, as well as a preparation method thereof, a pharmaceutical composition containing the compound, and application of the compound as a proline hydroxylase (PHD) inhibitor, the compound and the pharmaceutical composition containing the compound can be used in treating and / or preventing of PHD -activity- related diseases such as cardiovascular diseases, chronic kidneydisease, anemia, wounds, cancer, autoimmune diseases and the like. In the general formula (I), the definition of each substituent in the formula is the same as that in the specification.
Description
technical field [0001] The invention belongs to the field of medical technology, and in particular relates to a dihydropyrazolone compound, a preparation method thereof, a pharmaceutical composition containing the same, and its use for regulating proline hydroxylase (proline hydroxylase domain, PHD) activity , and then for the treatment and / or prevention of diseases associated with PHD activity. Background technique [0002] In a hypoxic environment, the body can spontaneously respond to hypoxia to maintain the body's ability to obtain oxygen. In 1992, Semenza et al. discovered a protein that can specifically bind to the hypoxia response element (HRE) of the erythropoietingene and affect the expression of certain genes. The protein is called hypoxia-inducible factor (HIF) (Semenza GL et al., Mol. Cell Biol., 1992, 12, 5447-5454). HIF has a wide range of target genes, which can affect the body's hematopoietic function, angiogenesis, iron ion transport, glucose utilization,...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More 
